This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles (OATP)

This study has been completed.
Information provided by:
Seoul National University Hospital Identifier:
First received: October 4, 2010
Last updated: January 4, 2011
Last verified: January 2011
This study aimed to explore the influence of organic anion transporting polypeptide1B1 (OATP1B1) genotype on pharmacokinetics, lipid lowering effect and lipid profiles after rosuvastatin administration.

Condition Intervention Phase
Organic Anion Transporting Polypeptide1B1 (OATP1B1) Rosuvastatin Drug: Rosuvastatin Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Influence of OATP1B1 Genotype on the Pharmacokinetics,Lipid Lowering Effect, and Lipid Profiles After Rosuvastatin Administration

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • pharmacokinetic parameters(Tmax,Cmax,AUC) of rosuvastatin [ Time Frame: Day 21 0h, 1h, 2h, 3h, 4h, 5h, 8h, 12h, 24h ]

Secondary Outcome Measures:
  • lipid panel(LDL,HDL,TG,Total cholesterol) [ Time Frame: Day 1 0h, Day 22 0h ]
  • lipid metabolites [ Time Frame: Day -1 0h, Day21 0h, 4h, 8h ]

Estimated Enrollment: 34
Study Start Date: October 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosuvastatin
rosuvastatin treatment
Drug: Rosuvastatin
20 mg once daily for 21 days

Detailed Description:

Open, one arm, single sequence study for healthy volunteers are investigated. Thirty four subjects may be enrolled.

Rosuvastatin are administered once a day for 21 days. Before and after rosuvastatin administration, PK, PD and lipid profiles are investigated.


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age: Between 20 to 50 years of age, inclusive (age based on the date to give the informed consent)
  • Weight: Over 55 kg, within ±20% of ideal body weight
  • Must be reliable and willing to make themselves available during the study period
  • Must be willing to give blood sample for genotyping

Exclusion Criteria:

  • History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease
  • History of a significant surgical resection of gastrointestinal tract except appendectomy
  • History or evidence of drug abuse
  • Use any medication during the last 14 days period before first dosing
  • Hypersensitivity to HMG-CoA reductase inhibitor
  • Judged to be inappropriate for the study by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01218347

Korea, Republic of
Clinical Trials Center, Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Kyung-Sang Yu, MD, PhD Seoul National University College of Medicine and Hospital
  More Information

Responsible Party: Kyung-Sang Yu/Professor, Seoul National University Hospital Identifier: NCT01218347     History of Changes
Other Study ID Numbers: SNUCPT10_Rosuvastatin_OATP1B1
Study First Received: October 4, 2010
Last Updated: January 4, 2011

Keywords provided by Seoul National University Hospital:

Additional relevant MeSH terms:
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on June 23, 2017